Clinical Commander

Back to dossier
cardio.cardiac-tamponade.hiv-related.v1PRODUCTION
cardio.cardiac-tamponade.hiv-related.v1

Cardiac tamponade — HIV-related pericardial effusion

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

HIV-related tamponade — broad etiology differential (TB, malignancy, opportunistic infection, HIV cardiomyopathy, drug reaction); pericardiocentesis for both diagnosis (full panel) + tamponade relief; ART optimization with IRIS-aware timing if ART-naive; STEROIDS AVOIDED in HIV+ per IMPI subgroup (KS reactivation risk)

Inputs
1
Actions
0
Advance rule
Set
Advance when

HIV-context tamponade physiology suspected

Patient inputs (10)

Modifies HIV care complexity, ART tolerance, drug interaction profile (DHHS 2024)

Compensatory tachycardia in tamponade physiology (ESC 2015)

CD4 stratifies opportunistic infection risk + drives steroid-avoidance decision (KS risk per IMPI HIV+ subgroup PMID 25199187); viral load drives ART urgency + IRIS risk (WHO 2024)

ART-naive vs experienced changes IRIS risk, regimen choice (rifampin requires efavirenz-based or DTG dose-adjusted ART), and treatment-failure suspicion (DHHS 2024)

Fever pattern informs differential — TB (subacute fever + night sweats), opportunistic infection, lymphoma (B-symptoms), HIV-related drug reaction (DHHS 2024)

Definitive bedside dx — chamber collapse, IVC, swinging heart; characterize effusion size + masses suggesting KS/lymphoma + fibrin strands suggesting TB (ESC 2015 Class I)

Baseline for nephrotoxic ART (TDF), RIPE drug dose-adjustment if TB, contrast use for chest CT (KDIGO 2024)

Baseline for ART hepatotoxicity (NVP), RIPE-induced hepatitis if TB, viral hepatitis co-infection screening (DHHS 2024)

Mediastinal lymphadenopathy + cavitary disease suggests TB; intrathoracic masses suggest KS/lymphoma; pulmonary consolidation suggests opportunistic pneumonia (DHHS 2024)

Hypotension is part of Beck triad; pulsus paradoxus measurement (Roy JAMA 2007 PMID 17456823)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningmdr_tb_resistance_in_hiv_co_infection
    Xpert MTB/RIF or culture susceptibility shows resistance to rifampin (RR-TB) or rifampin + INH (MDR-TB) in HIV+ TB pericarditis patient (WHO 2024 MDR-TB)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningopportunistic_fungal_pericarditis_cryptococcal_or_candida
    Cryptococcal antigen positive in pericardial fluid OR fungal culture positive (Candida, Cryptococcus, Aspergillus) — opportunistic fungal pericarditis in advanced HIV (CD4 <100) (IDSA 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_aids_defining_lymphoma_pericardial_invasion
    AIDS-related lymphoma (DLBCL, primary effusion lymphoma, plasmablastic) with pericardial invasion confirmed on cytology/flow cytometry/biopsy (NCCN AIDS-related lymphoma)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereiris_paradoxical_worsening_on_art_initiation
    Paradoxical worsening of pericardial disease 2-12 wk after ART initiation in HIV+ patient — IRIS reaction (WHO HIV 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereks_reactivation_or_progression_on_steroids_or_immunosuppression
    Kaposi sarcoma flare/reactivation on steroids or immunosuppressive therapy in HIV+ patient (Mayosi IMPI subgroup PMID 25199187)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

HIV-related pericardial effusion — pericardiocentesis + etiology-specific therapy (TB/KS/lymphoma/OI/HIV-CMP) + ART optimization with IRIS-aware timing + selective OI prophylaxis (no steroids per IMPI HIV+ subgroup)
axis: hiv_related_pericardial_drainage_plus_etiology_specific_therapy_plus_art_optimization
Selected axis "HIV-related pericardial effusion — pericardiocentesis + etiology-specific therapy (TB/KS/lymphoma/OI/HIV-CMP) + ART optimization with IRIS-aware timing + selective OI prophylaxis (no steroids per IMPI HIV+ subgroup)" by default fallback (first axis)
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus • IV • rapid bolus then reassess
    triggers: hypotension_pre_drainage
    Bridge preload to drainage (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids
    Bridge only — does not address obstruction (Roy JAMA 2007)
    rxcui 7512
  • rifampin
    first line
    antimycobacterial_rifamycin
    10 mg/kg PO daily (max 600 mg) • PO • daily × 6 mo if TB
    triggers: confirmed_or_high_probability_tb_pericarditis
    WHO 2024 — first-line; major CYP induction → ART regimen change required (efavirenz-based or DTG dose-doubled per WHO HIV/TB)
    rxcui 9384
  • isoniazid
    first line
    antimycobacterial_inh
    5 mg/kg PO daily + pyridoxine • PO • daily × 6 mo if TB
    triggers: confirmed_tb_pericarditis
    WHO 2024 — first-line; pyridoxine prevents neuropathy
    rxcui 6038
  • pyrazinamide
    first line
    antimycobacterial_pza
    25 mg/kg PO daily • PO • daily × 2 mo intensive if TB
    triggers: confirmed_tb_pericarditis
    WHO 2024 — intensive phase only
    rxcui 8987
  • ethambutol
    first line
    antimycobacterial_emb
    15-25 mg/kg PO daily • PO • daily × 2 mo intensive if TB
    triggers: confirmed_tb_pericarditis
    WHO 2024 — intensive phase; visual acuity monthly
    rxcui 4110
  • liposomal doxorubicin
    comorbidity specific
    anthracycline_liposomal
    20 mg/m² IV q3 wk × 4-8 cycles • IV • q3 wk
    triggers: kaposi_sarcoma_pericardial_invasion_confirmed
    AIDS-related KS — first-line per NCCN; coordinate with ART optimization (cardiotoxicity surveillance with serial echo)
    rxcui 214525
  • amphotericin B liposomal
    comorbidity specific
    antifungal_polyene
    3-4 mg/kg IV daily • IV • daily × 2 wk induction
    triggers: cryptococcal_pericarditis_confirmed
    IDSA 2024 cryptococcal disease guidelines — induction with flucytosine then fluconazole consolidation/maintenance
    rxcui 236594
  • ganciclovir
    comorbidity specific
    antiviral_nucleoside_analogue
    5 mg/kg IV q12h × 14-21 d induction • IV • q12h induction then valganciclovir maintenance
    triggers: cmv_pericarditis_confirmed_by_pcr_or_cytology
    DHHS 2024 — CMV end-organ disease in AIDS
    rxcui 4678
  • trimethoprim-sulfamethoxazole
    add on
    antibiotic_sulfonamide_combo
    160/800 mg PO daily • PO • daily
    triggers: CD4_lt_200_PJP_prophylaxis
    DHHS 2024 — universal PJP prophylaxis if CD4 <200; continue until CD4 >200 × 3 mo on ART
    rxcui 10180
  • azithromycin
    add on
    macrolide
    1200 mg PO weekly • PO • weekly
    triggers: CD4_lt_50_MAC_prophylaxis
    DHHS 2024 — MAC prophylaxis if CD4 <50; discontinue once CD4 >100 × 3 mo on ART
    rxcui 18631
  • fluconazole
    add on
    antifungal_azole
    400 mg PO daily induction → 200 mg maintenance • PO • daily
    triggers: cryptococcal_disease_consolidation_or_maintenance
    IDSA 2024 cryptococcal — consolidation 8 wk then maintenance until CD4 >100 sustained
    rxcui 4450
  • pyridoxine
    add on
    vitamin_b6
    25-50 mg PO daily • PO • daily concurrent with INH
    triggers: inh_co_administration_for_tb_pericarditis
    Standard INH co-administration — peripheral neuropathy prevention (WHO 2024)
    rxcui 684879

outpatient playbook — drug actions (4)

  1. 1. continue ART lifelong
    per regimen • PO • daily
    trigger: HIV+ ongoing
    DHHS 2024 — lifelong adherence
  2. 2. OI prophylaxis discontinuation as CD4 reconstitutes
    rxcui 10180
    discontinue TMP-SMX once CD4 >200 × 3 mo; discontinue azithromycin once CD4 >100 × 3 mo • N/A • discontinue
    trigger: CD4 reconstitution sustained
    DHHS 2024 — safe discontinuation criteria
  3. 3. completion of TB therapy if applicable at 6 mo
    completed; cure documentation • N/A • completed
    trigger: End of 6-mo RIPE if TB
    WHO 2024
  4. 4. diuretic for constriction symptoms if developing
    rxcui 4603
    furosemide 20-40 mg PO daily titrate • PO • daily
    trigger: Constriction symptoms
    Symptomatic relief while pericardiectomy evaluated (ESC 2015)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Subacute (days-weeks) dyspnea + Beck triad in known HIV+ patient (especially CD4 <200, endemic region) → HIV-related tamponade with broad etiology differential (Mayosi Heart 2017; Currier); Echo: pericardial effusion (often large >2 cm) ± fibrin strands ± masses (KS/lymphoma) + RV diastolic collapse + IVC plethora in HIV+ patient (ESC 2015); New HIV diagnosis (positive HIV antibody/PCR) prompted by pericardial effusion workup — universal HIV testing in any unexplained effusion (ESC 2015 Class I).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — HIV-related pericardial effusion** (cardio.cardiac-tamponade.hiv-related.v1).
Phenotype framing: Pericardial fluid panel: cell count + diff (lymphocytic = TB; neutrophilic = bacterial; eosinophilic = fungal/drug); cytology (KS spindle cells, lymphoma cells); AFB stain + Xpert MTB/RIF + ADA + IGRA (TB); fungal smear + culture + cryptococcal antigen (cryptococcosis, candidiasis); gram stain + bacterial culture; CMV PCR; chylomicron triglyceride (chyle); flow cytometry for lymphoma; pericardial biopsy if non-diagnostic fluid (ESC 2015; Currier)
Scope: HIV-related tamponade — broad etiology differential (TB, malignancy, opportunistic infection, HIV cardiomyopathy, drug reaction); pericardiocentesis for both diagnosis (full panel) + tamponade relief; ART optimization with IRIS-aware timing if ART-naive; STEROIDS AVOIDED in HIV+ per IMPI subgroup (KS reactivation risk)

No severity triggers fired against current inputs.

Plan

Regimen axis: **HIV-related pericardial effusion — pericardiocentesis + etiology-specific therapy (TB/KS/lymphoma/OI/HIV-CMP) + ART optimization with IRIS-aware timing + selective OI prophylaxis (no steroids per IMPI HIV+ subgroup)**.
1. normal saline 500-1000 mL bolus IV rapid bolus then reassess (isotonic_crystalloid, first line) — Bridge preload to drainage (ESC 2015)
2. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007)
3. rifampin 10 mg/kg PO daily (max 600 mg) PO daily × 6 mo if TB (antimycobacterial_rifamycin, first line) — WHO 2024 — first-line; major CYP induction → ART regimen change required (efavirenz-based or DTG dose-doubled per WHO HIV/TB)
4. isoniazid 5 mg/kg PO daily + pyridoxine PO daily × 6 mo if TB (antimycobacterial_inh, first line) — WHO 2024 — first-line; pyridoxine prevents neuropathy
5. pyrazinamide 25 mg/kg PO daily PO daily × 2 mo intensive if TB (antimycobacterial_pza, first line) — WHO 2024 — intensive phase only
6. ethambutol 15-25 mg/kg PO daily PO daily × 2 mo intensive if TB (antimycobacterial_emb, first line) — WHO 2024 — intensive phase; visual acuity monthly
7. liposomal doxorubicin 20 mg/m² IV q3 wk × 4-8 cycles IV q3 wk (anthracycline_liposomal, comorbidity specific) — AIDS-related KS — first-line per NCCN; coordinate with ART optimization (cardiotoxicity surveillance with serial echo)
8. amphotericin B liposomal 3-4 mg/kg IV daily IV daily × 2 wk induction (antifungal_polyene, comorbidity specific) — IDSA 2024 cryptococcal disease guidelines — induction with flucytosine then fluconazole consolidation/maintenance
9. ganciclovir 5 mg/kg IV q12h × 14-21 d induction IV q12h induction then valganciclovir maintenance (antiviral_nucleoside_analogue, comorbidity specific) — DHHS 2024 — CMV end-organ disease in AIDS
10. trimethoprim-sulfamethoxazole 160/800 mg PO daily PO daily (antibiotic_sulfonamide_combo, add on) — DHHS 2024 — universal PJP prophylaxis if CD4 <200; continue until CD4 >200 × 3 mo on ART
11. azithromycin 1200 mg PO weekly PO weekly (macrolide, add on) — DHHS 2024 — MAC prophylaxis if CD4 <50; discontinue once CD4 >100 × 3 mo on ART
12. fluconazole 400 mg PO daily induction → 200 mg maintenance PO daily (antifungal_azole, add on) — IDSA 2024 cryptococcal — consolidation 8 wk then maintenance until CD4 >100 sustained
13. pyridoxine 25-50 mg PO daily PO daily concurrent with INH (vitamin_b6, add on) — Standard INH co-administration — peripheral neuropathy prevention (WHO 2024)

Setting playbook (outpatient) — Long-term surveillance for constrictive pericarditis (~25% if TB); ART continuation with viral suppression goal; OI prophylaxis tapering as CD4 reconstitutes; secondary etiology surveillance (recurrent KS, lymphoma); pericardiectomy if constriction develops (DHHS 2024; ESC 2015)
14. continue ART lifelong per regimen PO daily — HIV+ ongoing (DHHS 2024 — lifelong adherence)
15. OI prophylaxis discontinuation as CD4 reconstitutes discontinue TMP-SMX once CD4 >200 × 3 mo; discontinue azithromycin once CD4 >100 × 3 mo N/A discontinue — CD4 reconstitution sustained (DHHS 2024 — safe discontinuation criteria)
16. completion of TB therapy if applicable at 6 mo completed; cure documentation N/A completed — End of 6-mo RIPE if TB (WHO 2024)
17. diuretic for constriction symptoms if developing furosemide 20-40 mg PO daily titrate PO daily — Constriction symptoms (Symptomatic relief while pericardiectomy evaluated (ESC 2015))

Non-pharmacologic actions:
- HIV care lifelong follow-up per DHHS 2024
- Cardiology follow-up at 3, 6, 12 mo then annually × 5 yr (constriction surveillance)
- ID follow-up per regimen
- Oncology follow-up if KS/lymphoma
- Cardiothoracic surgery referral if constriction develops
- Patient + family education ongoing for ART adherence + OI surveillance

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- Steroids_AVOID_in_HIV_positive_KS_reactivation_risk_per_IMPI_subgroup (Mayosi NEJM 2014 PMID 25199187)
- Rifampin_significant_drug_interactions_with_ART_PIs_avoid_with_protease_inhibitors_use_efavirenz_or_dtg_dose_doubled (WHO HIV/TB 2024)
- Tdf_avoid_eGFR_lt_30_switch_to_taf_or_abacavir (DHHS 2024)
- Dolutegravir_baseline_creatinine_rise_benign_not_renal_toxicity (label)
- Abacavir_HLA_B5701_test_required_before_initiation (DHHS 2024)
- Art_initiation_timing_2_to_8_wk_post_OI_treatment_to_minimize_IRIS (WHO 2024)
- Doxorubicin_baseline_LVEF_required_cumulative_dose_limit_550mg_m2 (NCCN)
- Flucytosine_dose_adjust_for_renal_function_marrow_suppression_surveillance (IDSA)
- Tmp_smx_avoid_g6pd_deficiency_or_severe_sulfa_allergy (label)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post (Adler 2015)
- echo post drain immediate then q24 48h x 7d then weekly then per response
- comprehensive fluid panel cytology AFB xpert ada igra fungal culture cryptococcal ag gram culture cmv pcr chyle triglyceride (ESC 2015; Currier)
- pericardial biopsy if non diagnostic fluid (ESC 2015)
- CD4 count trend q3 mo on ART (DHHS 2024)
- HIV viral load q4 to 12 wk during ART optimization (DHHS 2024)
- IRIS surveillance clinical assessment 2 to 12 wk post ART initiation (WHO 2024)
- ALT baseline then q2 4 wk for first 3 mo then per regimen (ART + RIPE hepatotoxicity)
- serum creatinine monthly during ART initiation more frequent if TDF (DHHS 2024)
- LVEF q3 mo during doxorubicin for KS (NCCN)
- CrAg titer for cryptococcal response q 2 wk during induction (IDSA)
- CMV PCR quantitative q 2 wk during treatment (DHHS 2024)
- visual acuity monthly for ethambutol if TB (WHO 2024)
- serial echo constriction surveillance at 3 6 12 mo (ESC 2015)

Setting (outpatient) monitoring:
- Echo at 3, 6, 12 mo then annually × 5 yr
- CMR + RH cath if constriction physiology suspected
- CD4 + VL q3-6 mo
- CRP per follow-up

Monitoring phase: Re-accumulation surveillance (echo q24-48h initially then weekly); ART adherence + virologic response (q4-12 wk VL); CD4 trend; IRIS surveillance 2-12 wk post-ART; etiology-specific therapy response; constriction surveillance (~25% in TB cases); drug toxicity (ART, RIPE, chemo) (DHHS 2024)

Disposition

Current setting: outpatient — Long-term surveillance for constrictive pericarditis (~25% if TB); ART continuation with viral suppression goal; OI prophylaxis tapering as CD4 reconstitutes; secondary etiology surveillance (recurrent KS, lymphoma); pericardiectomy if constriction develops (DHHS 2024; ESC 2015)

Disposition criteria:
- Long-term continuation under multidisciplinary team; pericardiectomy if constriction develops; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Symptomatic constrictive pericarditis (NYHA II-IV) → cardiothoracic surgery for pericardiectomy (ESC 2015 Class IIa)
- Recurrent effusion → re-drainage + diagnostic reconsideration (treatment failure? new OI? KS recurrence?)
- TB recurrence → ID + repeat workup + DOT re-engagement
- Late IRIS in HIV+ → ID + HIV team
- KS or lymphoma recurrence/progression → oncology emergent
- ART regimen failure (rising VL) → resistance testing + regimen switch per HIV team

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Xpert MTB/RIF or culture susceptibility shows resistance to rifampin (RR-TB) or rifampin + INH (MDR-TB) in HIV+ TB pericarditis patient (WHO 2024 MDR-TB)
- [LIFE_THREATENING] Cryptococcal antigen positive in pericardial fluid OR fungal culture positive (Candida, Cryptococcus, Aspergillus) — opportunistic fungal pericarditis in advanced HIV (CD4 <100) (IDSA 2024)
- [LIFE_THREATENING] AIDS-related lymphoma (DLBCL, primary effusion lymphoma, plasmablastic) with pericardial invasion confirmed on cytology/flow cytometry/biopsy (NCCN AIDS-related lymphoma)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) anchors drainage + workup baseline; IMPI trial (Mayosi NEJM 2014 PMID 25199187) anchors steroid AVOIDANCE in HIV+ TB pericarditis subgroup (KS reactivation risk); WHO Global TB Report 2024 + WHO TB treatment guidelines 2024 anchor RIPE regimen for TB etiology; WHO Consolidated HIV ART guidelines 2024 + DHHS HIV ART guidelines 2024 anchor ART optimization with IRIS-aware timing + OI prophylaxis; IDSA 2024 cryptococcal disease guidelines + DHHS OI guidelines 2024 anchor opportunistic infection management; NCCN AIDS-related KS + lymphoma anchor oncology pathway. Currier HIV cardiac complications and Sliwa HIV cardiac/Mayosi Heart 2017 anchor HIV-context epidemiology and multidisciplinary co-management. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 25199187) [PMID:25199187](https://pubmed.ncbi.nlm.nih.gov/25199187/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)
- Cited evidence (PMID 12122206) [PMID:12122206](https://pubmed.ncbi.nlm.nih.gov/12122206/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) anchors drainage + workup baseline; IMPI trial (Mayosi NEJM 2014 PMID 25199187) anchors steroid AVOIDANCE in HIV+ TB pericarditis subgroup (KS reactivation risk); WHO Global TB Report 2024 + WHO TB treatment guidelines 2024 anchor RIPE regimen for TB etiology; WHO Consolidated HIV ART guidelines 2024 + DHHS HIV ART guidelines 2024 anchor ART optimization with IRIS-aware timing + OI prophylaxis; IDSA 2024 cryptococcal disease guidelines + DHHS OI guidelines 2024 anchor opportunistic infection management; NCCN AIDS-related KS + lymphoma anchor oncology pathway. Currier HIV cardiac complications and Sliwa HIV cardiac/Mayosi Heart 2017 anchor HIV-context epidemiology and multidisciplinary co-management. — PMID:26320112
  • Cited evidence (PMID 25199187) — PMID:25199187
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 20656240) — PMID:20656240
  • Cited evidence (PMID 12122206) — PMID:12122206